# Photon-counting detector CT in oncology: a new era of cancer imaging

**Authors:** Elisa Bruno, Anna Palmisano, Enrico Camisassa, Davide Vignale, Carlo Tacchetti, Antonio Esposito

PMC · DOI: 10.1186/s13244-025-02176-2 · 2026-01-21

## TL;DR

Photon-counting detector CT improves cancer imaging with better resolution, less radiation, and enhanced tissue analysis.

## Contribution

Photon-counting detector CT introduces new imaging capabilities for oncology with spectral data and reduced artifacts.

## Key findings

- PCCT provides ultra-high spatial resolution and enhanced contrast-to-noise ratio.
- PCCT reduces contrast agent usage and radiation exposure compared to conventional CT.
- PCCT enables quantitative iodine uptake evaluation and improved detection of small lesions.

## Abstract

Oncologic imaging plays a critical role in the diagnosis, staging, treatment planning, and follow-up of cancer patients. Recent advancements in computed tomography, particularly the development of photon-counting detector CT (PCCT), have introduced new opportunities for improving diagnostic accuracy and tissue characterization, while reducing contrast agent usage and radiation exposure. By offering ultra-high spatial resolution, enhanced contrast-to-noise ratio, and intrinsic spectral capabilities, PCCT addresses many limitations of conventional energy-integrating detector CT (EID-CT) and unlocks new possibilities for quantitative imaging. This review explores the emerging applications of PCCT across various tumor types—including thoracic, abdominal, and musculoskeletal malignancies—highlighting its potential to improve cancer imaging and patient care.

Photon-counting detector CT (PCCT) offers several advantages in oncologic imaging, providing superior spatial resolution, spectral imaging capabilities, and reduced radiation dose, enhancing lesion characterization and precise treatment planning, making PCCT a valuable tool for personalized cancer care.

CT has a crucial role in oncological imaging, supporting diagnosis, staging, treatment planning and follow-up.Compared to EID-CT, PCCT offers higher spatial and contrast resolution, reduces artifacts and image noise and provides spectral data enabling quantitative assessment.PCCT may improve cancer imaging by increasing diagnostic accuracy, with better detection of small lesions, enhanced soft tissue contrast, and enabling quantitative iodine uptake evaluation.

CT has a crucial role in oncological imaging, supporting diagnosis, staging, treatment planning and follow-up.

Compared to EID-CT, PCCT offers higher spatial and contrast resolution, reduces artifacts and image noise and provides spectral data enabling quantitative assessment.

PCCT may improve cancer imaging by increasing diagnostic accuracy, with better detection of small lesions, enhanced soft tissue contrast, and enabling quantitative iodine uptake evaluation.

## Linked entities

- **Diseases:** cancer (MONDO:0004992)

## Full-text entities

- **Diseases:** lung nodules (MESH:D003074), EID (MESH:D000081042), Cancer (MESH:D009369), HCC (MESH:D006528), benign cysts (MESH:D003560), ovarian cancer (MESH:D010051), fibrosis (MESH:D005355), peritoneal (MESH:D010538), lung cancer (MESH:D008175), pulmonary artery thromboembolism (MESH:D011655), cirrhotic liver (MESH:D008103), lymphocele (MESH:D008210), Bladder cancer (MESH:D001749), hemorrhagic (MESH:D006470), liver tumor (MESH:D008113), gastric cancer (MESH:D013274), enchondroma (MESH:D002812), thromboembolic (MESH:D013923), Pancreas (MESH:D010190), obese (MESH:D009765), Peritoneum masses (MESH:C536030), LM (MESH:D008207), Kidney cancer (MESH:D007680), dyspnea (MESH:D004417), Oncologic (MESH:D000072716), thoracic, abdominal, and musculoskeletal malignancies (MESH:D000007), fatty metamorphosis (MESH:C536351), multiple myeloma (MESH:D009101), renal nodules (MESH:D016606), papillary thyroid carcinoma (MESH:D000077273), muscle-invasive bladder cancer (MESH:D000093284), PDAC (MESH:D021441), lytic lesions (MESH:D009059), renal cell carcinoma (MESH:D002292), defect (MESH:D000013), Colorectal cancer (MESH:D015179), PCCT (MESH:D009845), hematoma (MESH:D006406), cystic neoplasm (MESH:D018297), inflammation (MESH:D007249), lung lepidic adenocarcinoma (MESH:D000077192), lymphadenopathy (MESH:D008206), sacral fracture (MESH:C537221), breast cancer (MESH:D001943), lung disease (MESH:D008171), hyperdense renal lesions (MESH:D007674), Bone metastases (MESH:D009362), bone lesion (MESH:D001847), IPMN (MESH:D000077779), papillary neoplasia (MESH:C565310), pancreatic (MESH:D010195), emphysema (MESH:D004646), pathologic fractures (MESH:D005598), weight loss (MESH:D015431), osteolytic lesion (MESH:D030981), edema (MESH:D004487), calcifications (MESH:D002114), ischemia (MESH:D007511), jejunal adenocarcinoma (MESH:D007580)
- **Chemicals:** bismuth (MESH:D001729), BCT (-), uric acid (MESH:D014527), metal (MESH:D008670), calcium (MESH:D002118), gold (MESH:D006046), FDG (MESH:D019788), platinum (MESH:D010984), Iodine (MESH:D007455), water (MESH:D014867)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

13 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12824093/full.md

---
Source: https://tomesphere.com/paper/PMC12824093